Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
Quoin Pharmaceuticals (NASDAQ: QNRX) has released a new episode of its NETHERTON NOW video series featuring Professor Jemima Mellerio, a leading expert in genetic skin diseases. The video highlights the severe challenges of Netherton Syndrome, particularly in infants and children.
The release follows Quoin's recent achievement of Rare Pediatric Disease Designation from the FDA for its lead product candidate QRX003, which complements its existing Orphan Drug status from the EMA. Professor Mellerio emphasizes that Netherton Syndrome is a serious genetic condition with associated mortality, especially in young patients, requiring intensive daily treatment.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha pubblicato un nuovo episodio della serie video NETHERTON NOW con la partecipazione della Professoressa Jemima Mellerio, esperta di rilievo nelle malattie genetiche della pelle. Il video mette in luce le gravi difficoltà legate alla Sindrome di Netherton, soprattutto nei neonati e nei bambini.
Questa uscita segue il recente riconoscimento da parte della FDA con la designazione di Malattia Pediatrica Rara per il suo principale candidato farmaco QRX003, che si aggiunge allo status di Farmaco Orfano già ottenuto dall'EMA. La Professoressa Mellerio sottolinea come la Sindrome di Netherton sia una condizione genetica grave, con mortalità associata, soprattutto nei pazienti più giovani, che necessita di un trattamento intensivo quotidiano.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha lanzado un nuevo episodio de su serie de videos NETHERTON NOW con la participación de la Profesora Jemima Mellerio, una experta líder en enfermedades genéticas de la piel. El video destaca los graves desafíos del Síndrome de Netherton, especialmente en bebés y niños.
Este lanzamiento sigue al reciente logro de Quoin de la Designación de Enfermedad Pediátrica Rara por la FDA para su principal candidato a medicamento QRX003, que complementa su estatus de Medicamento Huérfano otorgado por la EMA. La Profesora Mellerio enfatiza que el Síndrome de Netherton es una condición genética grave con mortalidad asociada, especialmente en pacientes jóvenes, que requiere un tratamiento intensivo diario.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 유전성 피부 질환 분야의 선도 전문가인 제미마 멜레리오 교수가 출연하는 NETHERTON NOW 비디오 시리즈의 새 에피소드를 공개했습니다. 이 영상은 특히 영유아와 어린이에게 심각한 네더튼 증후군의 어려움을 조명합니다.
이번 공개는 Quoin이 주력 후보 약물 QRX003에 대해 FDA로부터 희귀 소아 질환 지정을 받은 최근 성과에 이어진 것으로, 이는 EMA의 희귀 의약품 지위와도 상호 보완됩니다. 멜레리오 교수는 네더튼 증후군이 특히 어린 환자에게 사망률이 높은 심각한 유전 질환이며, 매일 집중적인 치료가 필요하다고 강조합니다.
Quoin Pharmaceuticals (NASDAQ : QNRX) a publié un nouvel épisode de sa série vidéo NETHERTON NOW mettant en vedette la professeure Jemima Mellerio, experte reconnue des maladies génétiques de la peau. La vidéo met en avant les défis majeurs du syndrome de Netherton, notamment chez les nourrissons et les enfants.
Cette publication fait suite à l'obtention récente par Quoin de la désignation de maladie pédiatrique rare par la FDA pour son principal candidat médicament QRX003, qui complète son statut de médicament orphelin accordé par l'EMA. La professeure Mellerio souligne que le syndrome de Netherton est une maladie génétique grave, avec une mortalité associée, particulièrement chez les jeunes patients, nécessitant un traitement quotidien intensif.
Quoin Pharmaceuticals (NASDAQ: QNRX) hat eine neue Folge seiner NETHERTON NOW-Videoserie veröffentlicht, in der Professor Jemima Mellerio, eine führende Expertin für genetische Hautkrankheiten, zu sehen ist. Das Video hebt die schweren Herausforderungen des Netherton-Syndroms hervor, insbesondere bei Säuglingen und Kindern.
Die Veröffentlichung folgt auf Quoins jüngsten Erfolg, die Rare Pediatric Disease Designation von der FDA für seinen führenden Produktkandidaten QRX003 zu erhalten, was den bestehenden Orphan-Drug-Status der EMA ergänzt. Professor Mellerio betont, dass das Netherton-Syndrom eine ernste genetische Erkrankung mit einer damit verbundenen Sterblichkeit ist, vor allem bei jungen Patienten, die eine intensive tägliche Behandlung erfordert.
- FDA granted Rare Pediatric Disease Designation for QRX003 product candidate
- Company holds Orphan Drug status from European Medicines Agency (EMA)
- Ongoing awareness campaign NETHERTON NOW demonstrates commitment to disease education
- No current cure exists for Netherton Syndrome
- Limited clinical treatment options available for patients
Insights
Quoin's QRX003 received FDA Rare Pediatric Disease Designation, strengthening regulatory position for Netherton Syndrome treatment amid limited competition.
The release of Quoin's educational video featuring Professor Mellerio serves primarily as a visibility initiative, but the recently granted FDA Rare Pediatric Disease Designation for QRX003 represents meaningful regulatory advancement. This designation, combined with the existing Orphan Drug status from the European Medicines Agency, creates a robust regulatory framework that could accelerate development and commercialization pathways.
The Rare Pediatric Disease Designation is particularly significant as it may qualify Quoin for a Priority Review Voucher upon potential FDA approval. These vouchers can be used to expedite review of future products or can be sold to other companies—often fetching
Netherton Syndrome represents a highly specialized market with limited competition. The condition is characterized as a life-threatening genetic skin disorder particularly dangerous for infants and children, creating urgency for effective treatments. The current standard of care appears limited to symptomatic management rather than targeted therapies, positioning QRX003 to potentially address a critical unmet need.
While the press release doesn't provide clinical data or timelines for QRX003's development, the dual regulatory designations suggest Quoin is successfully navigating the regulatory pathway for rare disease drug development. For a small biotech company (
New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatments
ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of a new episode in its NETHERTON NOW video series. The episode features Professor Jemima Mellerio, a recognized authority in dermatology and genetic skin disorders.
In the video, Professor Mellerio, Consultant Dermatologist at St John’s Institute of Dermatology at Guy’s and St Thomas’ NHS Foundation Trust and Honorary Chair of Paediatric Dermatology at King’s College London, shares her perspective on the complex and life-threatening challenges of Netherton Syndrome, particularly in infants and young children.
“Netherton Syndrome is classified as a skin disease called ichthyosis. It's a genetic condition and we don't currently have a cure for it,” Mellerio said. “It's not just the way the skin appears. It's actually a very serious medical condition and there is associated mortality with it—particularly in young babies and small children.”
“This is a lifelong condition that requires intensive treatment every single day,” Mellerio added. “To have the prospect to be able to do proper research and to try and find more appropriate targeted treatments is brilliant. I'm delighted that the landscape is finally changing and might have a bit of light on the horizon for people living with this devastating condition.”
“Professor Mellerio brings an important clinical voice to the NETHERTON NOW series,” said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. “Her experience treating patients with genetic skin diseases highlights both the severity of this condition and the critical need for improved therapeutic options.”
The release of this video follows Quoin’s recent announcement that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for its lead product candidate, QRX003, for the treatment of Netherton Syndrome. Together with Orphan Drug status from the European Medicines Agency (EMA), this designation highlights the serious and underserved nature of the disease in pediatric patients.
“The experiences shared by Professor Mellerio speak directly to the challenges that children and families face from birth when living with Netherton Syndrome,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “This is a serious pediatric disease with limited clinical options, and we believe QRX003 has the potential to change that. The recent Rare Pediatric Disease Designation from the FDA further reinforces the urgency of our mission.”
The NETHERTON NOW campaign is an ongoing initiative from Quoin to raise awareness, improve education and elevate the voices of patients, caregivers and experts in the field. The full video featuring Mellerio is available at: https://nethertonnow.com
About QRX003
QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier. For more information about Quoin’s current clinical trials, please visit: https://quoinpharma.com/pipeline/#trials
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For more information about Netherton Syndrome, Quoin’s clinical programs, or to stay updated on the Netherton Now series, visit nethertonnow.com.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “aim,” “design,” “expect,” “hope,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential of QRX003 as a treatment for Netherton Syndrome; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company’s studies are successful in generating data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
What is the latest FDA designation received by Quoin Pharmaceuticals (QNRX) for QRX003?
What regulatory approvals does Quoin Pharmaceuticals (QNRX) have for its Netherton Syndrome treatment?
What is Netherton Syndrome according to Professor Mellerio?
Who is featured in Quoin Pharmaceuticals' latest NETHERTON NOW video?
